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LETTER
An n-of-one RCT for
intravenous immunoglobulin
G for inﬂammation in
hereditary neuropathy with
liability to pressure palsy
(HNPP)
BACKGROUND
Hereditary neuropathy with liability to
pressure palsy (HNPP; tomaculous neur-
opathy) is a rare autosomal dominant dis-
order caused by a loss of function of the
peripheral myelin protein 22 gene
(PMP22; OMIM #601097) for which no
curative treatment exists. Symptoms
consist of recurrent painless episodes of
focal sensory loss and muscle weakness,
which are often provoked by nerve com-
pression and resolve spontaneously within
days to months.1 In this report, we
describe the case of a female patient with
HNPP who initially presented with symp-
toms of a painful neuropathy which were
successfully treated with intravenous
immunoglobulin G (IVIg), and the results
of a double-blind, placebo-controlled
n-of-one trial to assess the effectiveness of
IVIg in this patient.
In 2002, a 35-year-old female patient
presented with a 15-month history of
neuropathic pain in the right leg, and
recurring episodes of weakness and
sensory loss in the legs which resolved
spontaneously after several weeks. Her
medical and family history was unremark-
able. Physical examination showed mild
proximal weakness of the left leg
(Medical Research Council (MRC) grade
4), severe weakness of the left foot exten-
sors (MRC 0–2), hypoalgesia of the left
hand and lower leg, and reduced tendon
reﬂexes with absent Achilles reﬂexes. All
additional investigations were normal,
except electromyographic (EMG) studies
which showed bilateral demyelinating
conduction blocks at ulnar nerve compres-
sion sites, prolonged distal motor latencies
of the ulnar, tibial, peroneal and median
nerves, and absent F-waves in peroneal
and right tibial nerves, consistent with
HNPP, but also with deﬁnite electrodiag-
nostic criteria for chronic inﬂammatory
demyelinating polyneuropathy (CIDP)
according to current European Federation
of Neurological Societies/Peripheral Nerve
Society guidelines.2 A preliminary diagno-
sis of CIDP was made and a DNA test for
suspected HNPP was ordered.
She was treated with IVIg (0.4 mg/kg/
day) for 5 days followed by maintenance
doses every 3 weeks, which led to
improvements in muscle strength and
resolution of pain. DNA analysis subse-
quently showed a deletion of 17p11.2
including the PMP22 gene, and a deﬁnite
diagnosis of HNPP was made, questioning
the need for continued IVIg treatment.
The patient consented to participate in a
double-blind, placebo-controlled n-of-one
trial to assess whether IVIg infusions led
to a clinically meaningful reduction in
pain and increase in muscle strength, and
to establish whether maintenance treat-
ment with IVIg was necessary. We provide
a summary of this trial, and the full
research report is available as online sup-
plementary material 1.
METHODS
During the 15-week n-of-one trial, IVIg
(0.4 mg/kg) and placebo (0.9% saline)
“trial” infusions (wrapped in tin foil for
patient and investigator blinding) were
administered in a random sequence which
was generated by the dispensing hospital
pharmacy. A week after each trial infusion,
we offered an optional “rescue infusion”
with the opposite treatment to ensure that
potentially beneﬁcial treatment would not
be withheld for longer than a week. The
interval between the last infusion (trial or
rescue) and the next trial infusion was
held constant at 3 weeks. Pain in the right
leg and self-reported muscle strength of
the left leg were scored three times per
week on a 14 cm visual analogue scale
(VAS; 0: ‘absence of pain’ or ‘paralysis’ to
14: ‘worst possible pain’ or ‘normal
strength’). Clinically meaningful effects
were deﬁned as at least 30% reduction in
pain compared with baseline,3 and 30%
increase in muscle strength. Side effects
were also recorded.
IVIg and placebo scores across the ﬁrst
7 days following trial infusions were com-
pared to determine the effects on pain
and muscle strength. We evaluated the
course of pain and muscle strength over
3 weeks following IVIg infusions to assess
the need for continued IVIg. Coefﬁcients
were calculated in SPSS V.20, followed by
Bayesian evaluation of informative
hypotheses and calculation of Bayes
factors using Bayesian evaluation of
inequality constrained hypotheses for
general statistical models (BIG),4 with
Bayes factors larger than 10 denoting
strong support for a hypothesis.5 Details
of the analyses and the data archive are
provided in online supplementary materi-
als 2 and 3.
RESULTS
The patient received four trial infusions
(3 placebo, 1 IVIg) and requested three
rescue infusions (all IVIg, after each
placebo infusion). The trial’s timeline and
VAS scores for pain and muscle strength
are shown in ﬁgure 1, demonstrating a
beneﬁcial effect of IVIg on both out-
comes. Statistical testing showed strong
support for the hypotheses that pain
decreases (Bayes factor 63.74) and muscle
strength increases (Bayes factor 61.51)
more rapidly and to a clinically meaning-
ful extent after IVIg compared with
placebo. We also found strong support for
the hypotheses that pain ﬁrst decreases
and then increases again (Bayes factor
13.78), and that muscle strength ﬁrst
increases and then decreases (Bayes factor
15.67) over 3 weeks following IVIg,
which supported the need for continued
IVIg infusions. No adverse effects were
reported.
Follow-up
During 12 years of follow-up, the interval
for IVIg infusions was successfully
increased to 5 weeks with a sustained clin-
ical response. Follow-up EMGs
(2003–2014) initially showed signs of
demyelination (prolonged distal motor
latencies and decreased nerve conduction
times), but over the years became more con-
sistent with stable axonal damage. The
patient’s quality of life has remained stable.
DISCUSSION
This case suggests that hereditary neuro-
pathies may coexist with immune-
mediated neuropathies. The conditions
may be difﬁcult to distinguish, because
their clinical presentation may be similar,
and electrophysiology or nerve biopsy
studies can be unhelpful in establishing
inﬂammatory demyelinating disease when
demyelination is already present due to
hereditary disease. Moreover, current
diagnostic guidelines consider the pres-
ence of a hereditary demyelinating neur-
opathy as a diagnostic exclusion criterion
for CIDP,2 although several case reports
for HNPP and other hereditary demyelin-
ating neuropathies suggest otherwise.6–10
Pain is atypical in hereditary neuropathies
and its presence may therefore indicate
coexisting inﬂammation. N-of-1 trials to
assess the effects of immunomodulatory
treatment may also help establish a diag-
nosis of coexisting inﬂammation and
guide treatment for individual patients.11
In conclusion, this report suggests that
some patients with hereditary neuropa-
thies may have coexisting inﬂammation
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and demonstrates the importance of its
timely recognition, because adequate
immunomodulatory treatment can consid-
erably improve patients’ symptoms and
quality of life.
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Figure 1 Trial timeline, administered infusions and VAS scores for pain and subjective muscle strength (IVIg, intravenous immunoglobulin G;
VAS, visual analogue scale).
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